期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 149, 期 -, 页码 95-106出版社
ELSEVIER
DOI: 10.1016/j.addr.2019.08.005
关键词
Sequential release; Angiogenesis; Hydrogel carriers; Growth factors
资金
- Maryland Stem Cell Fund [MSCRFF-3928]
- NCI Physical Sciences-Oncology Center [U54CA210173]
- Maryland Stem Cells Research Fund [MSCRFI-2784]
- American Heart Association [15EIA22530000]
In recent years, as the mechanisms of vasculogenesis and angiogenesis have been uncovered, the functions of various pro-angiogenic growth factors (GFs) and cytokines have been identified. Therefore, therapeutic angiogenesis, by delivery of GFs, has been sought as a treatment for many vascular diseases. However, direct injection of these protein drugs has proven to have limited clinical success due to their short half-lives and systemic off-target effects. To overcome this, hydrogel carriers have been developed to conjugate single or multiple GFs with controllable, sustained, and localized delivery. However, these attempts have failed to account for the temporal complexity of natural angiogenic pathways, resulting in limited therapeutic effects. Recently, the emerging ideas of optimal sequential delivery of multiple GFs have been suggested to better mimic the biological processes and to enhance therapeutic angiogenesis. Incorporating sequential release into drug delivery platforms will likely promote the formation of neovasculature and generate vast therapeutic potential. (C) 2019 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据